Novartis is launching a Challenge for a recently introduced drug in the market that is linked with post-marketing adverse event case reports following administration of the drug in the human eye.
A small number of patients experienced adverse events termed as “retinal vasculitis” and/or “retinal vascular occlusion” that may result in severe vision loss and/or decreased visual acuity. To understand these phenomena, the Seeker desires a systems pharmacology model that takes into account interactions between the drug, its target, and the ocular inflammatory process.
The submission to the Challenge should include the following:
- A detailed description of the proposed Solution and how it addresses each Technical Requirement presented in the Detailed Description of the Challenge. This should also include a thorough description of the algorithm used in the Solution accompanied by a well-articulated rationale for the method employed.
- A simplified block diagram, with legend, of the systems pharmacology model.
- Output from the proposed algorithm as applied to specified parameters.
- For only the top ranked submissions, the Seeker may request the source code and/or an executable with sufficient documentation to enable the Seeker to compile, execute the algorithm, and validate the method using additional internal data.
To receive an award, the Solvers will have to transfer to the Seeker their exclusive intellectual property (IP) rights to the solution.
Studying the pharmacological effects of drugs injected into the human eye is difficult because traditional sampling methods are invasive. Therefore, the Seeker desires a computational model that accurately simulates the systems pharmacology of an administered drug.
This is a Reduction to Practice Challenge that requires written documentation, output from the proposed algorithm, and submission of the source code and/or an executable for validation, if requested by the Seeker.
Awards:- $ 75,000